ArriVent BioPharma Inc

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

AVBP$14.16+3.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets


· · March 31, · · December 31, ·
· 2025 · 2024
Assets · ·
Current assets: · ·
Cash and cash equivalents	$49,865	$74,293
Short-term investments	126,212	144,570
Prepaid expenses and other current assets	9,708	8,116
Total current assets	185,785	226,979
Long-term investments	29,414	47,683
Right of use assets – operating leases	120	154
Other assets	176	126
Total assets	$215,495	$274,942

Commitments and contingencies (Note 7)

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$4,364	$3,782
Accrued expenses	8,451	13,330
Operating lease liabilities	138	162
Total current liabilities	12,953	17,274
Operating lease liabilities, net of current amount	—	14
Total liabilities	12,953	17,288

Stockholders’ equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 34,040,996 and 33,706,765 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	4	3
Additional paid-in capital	505,275	496,195
Accumulated deficit	(302,720)	(238,333)
Accumulated other comprehensive loss	(17)	(211)
Total stockholders’ equity	202,542	257,654
Total liabilities and stockholders’ equity	$215,495	$274,942

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.